Manganese superoxide dismutase‐plasmid/liposome (MnSOD‐PL) administration protects mice from esophagitis associated with fractionated radiation
Open Access
- 19 July 2001
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 96 (4) , 221-231
- https://doi.org/10.1002/ijc.1023
Abstract
Intraesophageal administration of manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) prior to single fraction radiation has been shown to protect mice from lethal esophagitis. In our study, C3H/HeNsd mice received fractionated radiation in two protocols: (i) 18 Gy daily for four days with MnSOD-PL administration 24 hr prior to the first and third fraction, or (ii) 12 Gy daily for six days with MnSOD-PL 24 hr prior to the first, third, and fifth fraction. Control radiated mice received either no liposomes only or LacZ (bacterial β-galactosidase gene)-plasmid/liposome (LacZ-PL) by the same schedules. We measured thiol depletion and lipid peroxidation (LP) in whole esophagus and tested the effectiveness of a new plasmid, hemagglutinin (HA) epitope-tagged MnSOD (HA-MnSOD). In fractionation protocols, mice receiving MnSOD-PL, but not LacZ-PL (200 μl of plasmid/liposomes containing 200 μg of plasmid DNA), showed a significant reduction in morbidity, decreased weight loss, and improved survival. Four and seven days after 37 Gy single fraction radiation, the esophagus demonstrated a significant increase in peroxidized lipids and reduction in overall antioxidant levels, reduced thiols, and decreased glutathione (GSH). These reductions were modulated by MnSOD-PL administration. The HA-MnSOD plasmid product was detected in the basal layers of the esophageal epithelium 24 hr after administration and provided significant radiation protection compared to glutathione peroxidase-plasmid/liposome (GPX-PL), or liposomes containing MnSOD protein, vitamin E, co-enzyme Q10, or 21-aminosteroid. Thus, MnSOD-PL administration significantly improved tolerance to fractionated radiation and modulated radiation effects on levels of GSH and lipid peroxidation (LP). These studies provide further support for translation of MnSOD-PL treatment into human esophageal radiation protection.Keywords
This publication has 45 references indexed in Scilit:
- Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancerRadiation Oncology Investigations, 1999
- Non-random peroxidation of different classes of membrane phospholipids in live cells detected by metabolically integrated cis-parinaric acidBiochimica et Biophysica Acta (BBA) - Biomembranes, 1996
- AmifostineDrugs, 1995
- Development of multifield three‐dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogramRadiation Oncology Investigations, 1995
- Formation of F2‐isoprostanes during aortic endothelial cell‐mediated oxidation of low density lipoproteinFEBS Letters, 1994
- The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocolInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non–small cell lung cancerCancer, 1993
- Low radioprotection by thiol in lung: the role of local tissue oxygenationEuropean Journal of Cancer and Clinical Oncology, 1983